title: Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier.
authors.affiliation: Fondazione IRCCS Institute of Neurology Carlo Besta, Milan, Italy. silke.krol@ifom.eu
authors.forename: Silke
authors.initials: S
authors.lastname: Krol
authors.forename: Richard
authors.initials: R
authors.lastname: Macrez
authors.forename: Fabian
authors.initials: F
authors.lastname: Docagne
authors.forename: Gilles
authors.initials: G
authors.lastname: Defer
authors.forename: Sophie
authors.initials: S
authors.lastname: Laurent
authors.forename: Masoud
authors.initials: M
authors.lastname: Rahman
authors.forename: Mohammad J
authors.initials: MJ
authors.lastname: Hajipour
authors.forename: Patrick G
authors.initials: PG
authors.lastname: Kehoe
authors.forename: Morteza
authors.initials: M
authors.lastname: Mahmoudi
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000503:physiopathology; D001812:Blood-Brain Barrier / Q000187:drug effects; D001920:Bradykinin / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D015140:Dementia, Vascular / Q000188:drug therapy / Q000503:physiopathology; D016503:Drug Delivery Systems; D004827:Epilepsy / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D008581:Meningitis / Q000503:physiopathology; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000503:physiopathology*; D053758:Nanoparticles / Q000627:therapeutic use* / Q000633:toxicity; D017382:Reactive Oxygen Species / Q000378:metabolism; D020521:Stroke / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D017382:Reactive Oxygen Species; D001920:Bradykinin